<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112577</url>
  </required_header>
  <id_info>
    <org_study_id>R3500-AS-1633</org_study_id>
    <secondary_id>2016-003165-26</secondary_id>
    <secondary_id>SAR440340</secondary_id>
    <nct_id>NCT03112577</nct_id>
  </id_info>
  <brief_title>Study of REGN3500 and Dupilumab in Patients With Asthma</brief_title>
  <official_title>A Randomized, Placebo-controlled, Parallel Panel Study to Assess the Effects of REGN3500, Dupilumab, and Combination of REGN3500 Plus Dupilumab on Markers of Inflammation After Bronchial Allergen Challenge in Patients With Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with
      placebo, on changes in inflammatory gene expression signatures in sputum induced after a
      bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after
      treatment initiation compared with those at screening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">January 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in bronchial allergen challenge (BAC)-induced changes in sputum inflammatory markers in individuals treated with REGN3500, dupilumab and the combination of REGN3500 plus dupilumab or placebo</measure>
    <time_frame>Screening (pre-treatment) to week 4 after treatment initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline to week 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of TEAEs</measure>
    <time_frame>Baseline to week 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration-time profile of REGN3500</measure>
    <time_frame>Baseline to week 42</time_frame>
    <description>Assessed by maximum plasma concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration-time profile of REGN3500: Tmax (time at Cmax)</measure>
    <time_frame>Baseline to week 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration-time profile of REGN3500: AUClast (area under the curve to the last measurable concentration)</measure>
    <time_frame>Baseline to week 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of REGN3500 and dupilumab</measure>
    <time_frame>Baseline to week 42</time_frame>
    <description>Assessed by measurement of anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of total IL-33 after single IV dose</measure>
    <time_frame>Up to Week 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the BAC-induced changes in sputum inflammatory mRNA signature in individual patients treated with fluticasone</measure>
    <time_frame>Screening (pre-treatment) to day 4 after treatment initiation</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Asthma, Allergic</condition>
  <arm_group>
    <arm_group_label>REGN3500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN3500: masked and randomized dosing regimen per protocol (part 1 only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN3500 plus dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo: masked and randomized dosing regimen per protocol (part 1 only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone propionate: open label dosing regimen per protocol (part 2 only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN3500</intervention_name>
    <description>Intravenous (IV) use</description>
    <arm_group_label>REGN3500</arm_group_label>
    <arm_group_label>REGN3500 plus dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Subcutaneous (SC) use</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_label>REGN3500 plus dupilumab</arm_group_label>
    <other_name>Dupixent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate</intervention_name>
    <description>Inhalation use</description>
    <arm_group_label>Fluticasone propionate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        KEY Inclusion Criteria:

          1. Male or female aged between 18 and 60 years

          2. Has a Body Mass Index {BMI) of 17 to 33 kg/m2 at pre-study screening

          3. Has a history of mild allergic asthma for at least 6 months

          4. Is a non-smoker or ex-smoker for at least 12 months

        KEY Exclusion Criteria:

          1. Has a history of life-threatening asthma

          2. Has been hospitalized or has attended the emergency room for asthma in the 12 months
             prior to screening

          3. Has a history of severe allergies or history of an anaphylactic reaction

          4. Has a history of drug or alcohol abuse within a year prior to the screening visit

        Note: other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hammersmith Medicine Research</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Respiratory Clinical Trials Ltd</name>
      <address>
        <city>London</city>
        <zip>W1G 8HU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

